PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer

Protein arginine methyl transferase 1 (PRMT1) was shown to be up-regulated in cancers and important for cancer cell proliferation. However, the role of PRMT1 in lung cancer progression and metastasis remains incompletely understood. In the present study, we show that PRMT1 is an important regulator...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of biological chemistry Vol. 290; no. 21; pp. 13479 - 13489
Main Authors Avasarala, Sreedevi, Van Scoyk, Michelle, Karuppusamy Rathinam, Manoj Kumar, Zerayesus, Sereke, Zhao, Xiangmin, Zhang, Wei, Pergande, Melissa R., Borgia, Jeffrey A., DeGregori, James, Port, J. David, Winn, Robert A., Bikkavilli, Rama Kamesh
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 22.05.2015
American Society for Biochemistry and Molecular Biology
Subjects
Online AccessGet full text
ISSN0021-9258
1083-351X
1083-351X
DOI10.1074/jbc.M114.636050

Cover

More Information
Summary:Protein arginine methyl transferase 1 (PRMT1) was shown to be up-regulated in cancers and important for cancer cell proliferation. However, the role of PRMT1 in lung cancer progression and metastasis remains incompletely understood. In the present study, we show that PRMT1 is an important regulator of epithelial-mesenchymal transition (EMT), cancer cell migration, and invasion, which are essential processes during cancer progression, and metastasis. Additionally, we have identified Twist1, a basic helix-loop-helix transcription factor and a well-known E-cadherin repressor, as a novel PRMT1 substrate. Taken together, we show that PRMT1 is a novel regulator of EMT and arginine 34 (Arg-34) methylation of Twist1 as a unique “methyl arginine mark” for active E-cadherin repression. Therefore, targeting PRMT1-mediated Twist1 methylation might represent a novel strategy for developing new anti-invasive/anti-metastatic drugs. Moreover, methylated Twist1 (Arg-34), as such, could also emerge as a potential important biomarker for lung cancer. Background: PRMT1 is up-regulated in lung cancer. Results: PRMT1 is a novel regulator of EMT and Twist1 is a new PRMT1 substrate. Conclusion: PRMT1-methylation of Twist1 is required for active E-cadherin repression. Significance: Targeting PRMT1-mediated Twist1 methylation might represent a novel strategy for developing new anti-invasive/anti-metastatic drugs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-9258
1083-351X
1083-351X
DOI:10.1074/jbc.M114.636050